^
Association details:
| Biomarker: | KRAS G12R |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | gemcitabine (DNA synthesis inhibitor) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic indicators of KRAS G12X mutations in pancreatic cancer.
Published date:
01/17/2023
Excerpt:
The patients with KRAS G12R mutant tumors had significantly longer median real-world overall survival (mRWOS) compared to G12D (452 vs 358 days, HR 0.82, CI 0.74 – 0.9, p < 0.0001). This difference persisted regardless of treatment with FOLFIRINOX or gemcitabine plus nab-paclitaxel....Patients with KRAS G12R variants has improved rwOS compared to G12D irrespective of the chemotherapy regimen administered.
DOI:
10.1200/JCO.2023.41.3_suppl.735
